New York University

OCCC and POIETO host AI symposium for more than 300, new micro-credential in AI established

Retrieved on: 
星期二, 二月 27, 2024

OKLAHOMA CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Oklahoma City Community College (OCCC) and POIETO hosted more than 300 attendees at the inaugural Responsible AI in Education Symposium on Feb. 23.

Key Points: 
  • OKLAHOMA CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Oklahoma City Community College (OCCC) and POIETO hosted more than 300 attendees at the inaugural Responsible AI in Education Symposium on Feb. 23.
  • "Oklahoma City Community College is dedicated to advancing responsible AI practices in higher educational settings," said Dr. Mautra Staley Jones, president of OCCC.
  • "The Responsible AI in Education Symposium's engaging speakers, panels and workshops presented OCCC faculty and administrative staff with valuable insight on how to leverage AI to support academic and professional excellence."
  • Distinguished speakers from OCCC, University of Central Oklahoma, Oklahoma State University, Oklahoma City University, First Americans Museum, Oklahoma Contemporary, Robinson Park, the Oklahoma Office of Educational Quality and Accountability, ClearKinetic, BaB, Feminist AI, and POIETO also contributed their expertise.

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
星期三, 二月 21, 2024

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Alerus Financial Corporation Names Forrest Wilson Chief Retirement Services Officer

Retrieved on: 
星期四, 二月 22, 2024

Alerus Financial Corporation (Nasdaq: ALRS) announced today that Forrest Wilson will join Alerus as Executive Vice President and Chief Retirement Services Officer, effective February 26, 2024.

Key Points: 
  • Alerus Financial Corporation (Nasdaq: ALRS) announced today that Forrest Wilson will join Alerus as Executive Vice President and Chief Retirement Services Officer, effective February 26, 2024.
  • A well-rounded retirement industry veteran, Mr. Wilson brings over 25 years of experience on both the platform/recordkeeping and investment sides of the retirement business.
  • As Chief Retirement Services Officer, Mr. Wilson will be responsible for the overall leadership and direction of Alerus’ retirement and benefits division, which serves thousands of third-party advisors, over 8,000 employer-sponsored retirement plans, and approximately 474,000 plan participants nationwide.
  • “Forrest is widely experienced and well known in the retirement services industry,” said President and Chief Executive Officer Katie Lorenson.

Goulston & Storrs Attorney Rumi Tran Named a 2024 LCLD Pathfinder

Retrieved on: 
星期二, 二月 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Goulston & Storrs , an Am Law 200 firm, is pleased to announce that Rumi Tran has been selected for the Leadership Council on Legal Diversity (LCLD) 2024 Pathfinder program, which identifies, connects, and trains high-performing, early-career attorneys from diverse backgrounds on foundational leadership and relationship-building skills.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Goulston & Storrs , an Am Law 200 firm, is pleased to announce that Rumi Tran has been selected for the Leadership Council on Legal Diversity (LCLD) 2024 Pathfinder program, which identifies, connects, and trains high-performing, early-career attorneys from diverse backgrounds on foundational leadership and relationship-building skills.
  • She embodies the qualities we look for in our future leaders, and this Pathfinder program will help her to continue to hone her legal, business, and management skills," said Bill Dillon, Co-Managing Director of Goulston & Storrs.
  • "We look forward to her continued contributions to our firm as she moves to the next level of her career."
  • The Pathfinder program was conceived as a supplement to training initiatives already in place at LCLD Member corporations and law firms.

Kasowitz: Penn's Meritless Motion to Dismiss the Lawsuit Challenging Penn's Pervasive Antisemitism Only Proves the Need for the Lawsuit in the First Place

Retrieved on: 
星期三, 二月 14, 2024

Marc E. Kasowitz, partner at Kasowitz Benson Torres, stated:  "Just weeks ago, Penn's president refused to confirm to Congress that calling for the genocide of Jews violates Penn's code of conduct.

Key Points: 
  • Marc E. Kasowitz, partner at Kasowitz Benson Torres, stated:  "Just weeks ago, Penn's president refused to confirm to Congress that calling for the genocide of Jews violates Penn's code of conduct.
  • Now, in its meritless motion to dismiss, Penn, while trying to downplay the virulent antisemitism it has tolerated and enabled for so long on its campus, also says that it should be trusted to fix the problem.
  • But since that infamous testimony, the antisemitic hatred, discrimination, and harassment permeating Penn's campus has if anything worsened.
  • Penn's motion only underscores the need for the lawsuit—unless compelled to, Penn will not change."

Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors

Retrieved on: 
星期二, 一月 16, 2024

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors.
  • Ms. Burrell currently serves as Chief Financial Officer of Beam Therapeutics.
  • “We are very pleased to welcome Ms. Burrell to our board.
  • “This is an important moment for Rapport as the company prepares for both important clinical milestones and the complexities of the biotech financial landscape,” said Ms. Burrell.

American Foundation for Suicide Prevention Welcomes 2024 National Board Members

Retrieved on: 
星期三, 一月 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- The American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization, is pleased to announce its 2024 National Board of Directors.

Key Points: 
  • NEW YORK, Jan. 10, 2024 /PRNewswire/ -- The American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization, is pleased to announce its 2024 National Board of Directors.
  • Board members oversee the organization's efforts to empower the public through suicide prevention research, education, support and advocacy.
  • It's through the leadership and dedication of those who serve on the National Board that AFSP will advance suicide prevention in our country," said AFSP Chief Executive Officer Robert Gebbia .
  • The American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide, including those who have experienced a loss .

Walden Macht & Haran LLP Files Lawsuit Against NYU Langone Health on Behalf of World-Renowned Cancer Researcher for Unlawful Termination

Retrieved on: 
星期五, 十一月 17, 2023

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.
  • Dr. Neel may be the first fired for pro-Israel and anti-antisemitic re-posts on X, the social media site formerly known as Twitter.
  • According to the lawsuit, Dr. Neel “became a political casualty of NYULH’s effort to terminate” the physician who posted pro-Hamas content.
  • Partner Milton Williams leads the Walden Macht & Haran team representing Dr. Neel and includes senior counsel Daniel Chirlin and associate James Meehan.

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Retrieved on: 
星期五, 十一月 10, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty (CAM-E) drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • The data will be presented by Dr. Man-Fung Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong, in Poster Hall C on Monday November 13 from 1-2 pm ET.
  • “ALG-000184 appears to have best-in-class antiviral properties which are also unique compared to other drug classes being evaluated for the treatment of chronic hepatitis B (CHB).
  • If the trends observed to date continue, ALG-000184 has the potential to become a cornerstone therapy in the treatment of CHB.
  • The antiviral effects of ALG-000184 presented at AASLD indicate that this drug is achieving significant viral suppression, likely via inhibition of cccDNA synthesis.

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Retrieved on: 
星期二, 十二月 12, 2023

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024.
  • “David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value.
  • His past experiences will help Calidi move forward as a company, advancing our portfolio of cancer immunotherapies into later stage clinical trials,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • “I look forward to guiding Calidi’s team and helping them improve operational excellence as they mature their organization.”